Resize Text Search
  • Call 888.905.6071
  • Doctors offering 24/7 online appointment scheduling
  • Request an appointment
  • MyChart current patient scheduling
General Inquiries

Summa Health System honored by the Conquer Cancer Foundation

Date: 06.25.2014
Contact: Jim Gosky Phone: (234) 312-5052

 Summa Health System
Dr. R. Douglas Trochelman (center) and Dr. Sameer Mahesh
(right) of the Summa Cancer Institute accept the Conquer
Cancer Foundation Award from W. Charles Penley, MD,
of the Conquer Cancer Foundation Board of Directors.
Download Full Size Image
AKRON, OH June 25, 2014 – Summa Health System announced today that it is one of only eight community oncology practices in the country recognized by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) for its commitment to high-quality clinical trials programs. As a recipient of the Conquer Cancer Foundation Award, Summa is being honored for its contribution to the improvement of cancer care through clinical research in a community-based setting. 

Practices were selected to receive the award based on several different criteria, which emphasize high patient accrual in clinical trials by overcoming barriers to enrollment. In 2013, Summa Cancer Institute accrued 171 patients to clinical trials, a number that represented 12 percent of the Institute’s total number of cancer patients. Nationally, this accrual number is just two percent. Currently, there are more than 100 active cancer clinical trials at Summa, while treatment and research efforts cover more than 40 different disease types. An additional criterion for the award involved programs that serve and connect with underrepresented populations in their communities. 

“We are honored to be chosen for this award,” said R. Douglas Trochelman, M.D., system medical director for the Summa Cancer Institute. “Our team strives daily to provide our patients with the most comprehensive care available. In many cases, this means offering breakthrough clinical trials and treatment options not available elsewhere.”

“The Conquer Cancer Foundation of the American Society of Clinical Oncology is pleased to honor Summa Health System with the Clinical Trials Participation Award for providing patients with access to high-quality clinical research that furthers our progress against cancer,” said W. Charles Penley, M.D., FASCO, chair of the Conquer Cancer Foundation Board of Directors.  

The Clinical Trials Participation Award is funded through the Conquer Cancer Foundation of ASCO with the support of the Coalition of Cancer Cooperative Groups. The award was established in 2003. 

About Summa Health System

Summa Health System is one of the largest integrated healthcare delivery systems in Ohio and is one of only two health systems in northeast Ohio accredited by the American College of Radiation. Encompassing a network of hospitals, community health centers, a health plan, a physician-hospital organization, a multi-specialty physician organization, research programs and the Summa Foundation, Summa Health System is nationally renowned for excellence in patient care and for exceptional approaches to healthcare delivery. Summa's clinical services are consistently recognized by the American Nurses Credentialing Center (Magnet® status), U.S. News and World Report, Thomson Reuters and The Leapfrog Group. Summa also is a founding partner of the Austen BioInnovation Institute in Akron. For more information, visit or find us on Facebook at and Twitter at 

About the Conquer Cancer Foundation

The Conquer Cancer Foundation (CCF) was created by the world’s foremost cancer doctors of the American Society of Clinical Oncology to seek dramatic advances in the prevention, treatment and cures of all types of cancer. Toward the vision of a world free from the fear of cancer, CCF works to conquer this disease by funding breakthrough cancer research and sharing cutting-edge knowledge with patients and physicians worldwide, and by improving quality of care and access to care, enhancing the lives of all who are touched by cancer. For more information, visit